- N
Neuvivo
- Ari Azhir
Ari Azhir is a highly experienced executive in the biopharmaceutical industry, currently serving as the Chief Executive Officer of Neuvivo since January 2020, leading efforts in developing therapeutics for Amyotrophic Lateral Sclerosis (ALS) and neurodegenerative diseases. Ari's expertise includes founding and managing several biopharmaceutical companies, such as Neurocea Pharmaceuticals and Neuraltus Pharmaceuticals, with a focus on innovative therapeutics for neurodegenerative disorders. As a member of the UCSF Translational Catalyst Advisory Board, Ari contributes to advancing clinical and translational science. Ari's educational background includes a PhD in Biophysics and dual BSc degrees in Biochemistry and Mathematics from King's College London, complemented by postgraduate studies in Biophysics at the University of Liège.
Org chart
Teams
This person is not in any teams
Offices
This person is not in any offices
Neuvivo
Neuvivo is dedicated to creating therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. We have developed a patented macrophage-targeted technology, NP001, that addresses chronic inflammation, a key factor in the progressive loss of motor function in ALS. NP001 has received Orphan Drug and Fast Track designation by the FDA as it addresses a clear unmet medical need. We are working to move this compound toward approval and delivering an effective and safe new treatment for ALS.
